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Abstract
Background: Research examining the effects of oxytocin (OT) interventions on psychiatric, social-behavioral, and
social-cognitive outcomes regularly collect peripheral levels of OT as markers of central bioavailability. Such
inferences rest on the assumption that central and peripheral levels of OT are directly associated. However,
conflicting evidence from coordinated sampling of central and peripheral OT question the validity of this
assumption. The purpose of this meta-analysis is to evaluate the correlation between central and peripheral OT, as
well as to account for potential heterogeneity in the literature.
Methods/design: Studies that report coordinated sampling of central and peripheral OT in humans and animals
will be identified. Research investigating concentrations in both basal states and after exogenous administration will
be considered. PubMed and Embase databases will be searched, along with citation lists of retrieved articles.
Peer-reviewed studies written in English published from 1971 onwards will be included in the meta-analysis.
Data will be extracted from eligible studies for a random-effects meta-analysis. For each study, a summary
effect size, heterogeneity, risk of bias, publication bias, and the effect of categorical and continuous
moderator variables will be determined.
Discussion: This systematic review and meta-analysis will identify and synthesize evidence to determine if
there is an association between central and peripheral OT concentrations. If significant associations are
observed, evidence would provide a rationale for future research to use peripheral measures as a proxy for
central OT concentrations.
Systematic review registration: PROSPERO CRD42015027864
Keywords: Oxytocin, Plasma concentration, Cerebrospinal fluid concentration, ELISA, RIA, Systematic review,
Meta-analysis, Protocol
Background
Oxytocin (OT) is a neuropeptide that is primarily
synthesized in the paraventricular and supraoptical
nuclei of the hypothalamus. OT plays a vital role in
facilitating a range of physiological functions, such as
labor induction and lactation [1]. However, recent
research interest has focused more on its effects on
social cognitive functions including emotion recognition,
trust, and intersubjective selectivity [2–4]. Alongside these
efforts determining the role of OT in typical behavior and
cognition, research began to investigate the efficacy of
this neuropeptide in the treatment of psychiatric
disorders—such as autism spectrum disorder [5] and
schizophrenia [6]—and the overall role of the OT
system in psychopathology.
Three broad research approaches have been adopted
to better understand the role of OT in cognition,
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behavior, and psychiatric illness: (i) the comparison of a
psychological outcome measure or neurobiological effect
after OT and placebo treatment; (ii) the comparison of
basal OT concentrations between a pathological (e.g.,
psychiatric) and non-pathological control group; and (iii)
the assessment of basal OT concentration covariance
with various psychological or other biological phenom-
ena. While central to the latter two methods in this list,
peripheral concentrations of OT (e.g., blood plasma,
saliva, urine) have been assessed within each of these
research traditions, typically in an effort to approximate
central OT concentrations and/or central bioavailability
after OT administration. Using peripheral OT concentra-
tions to index central concentrations is obviously appeal-
ing given the invasive methods required to collect
centrally circulating fluids in humans, such as cerebro-
spinal fluid (CSF). However, the relationship between
central and peripheral OT concentrations remains
unclear. Although some animal research indicates that
central release from the hypothalamus and peripheral
release via the posterior pituitary is coordinated [7–9],
other research does not support this [10, 11]. Research is
also mixed in humans, with some results consistent with
related levels of central and peripheral endogenous OT
[12], while others report no significant associations [13].
In relation to exogenous OT, one human study found
that peripheral and central levels were not related after
intranasal administration; however, as the authors of the
study acknowledge, the small sample size suggest caution
in interpreting these results [14]. Together, it appears
unclear if peripheral OT measures can be used as a proxy
for central nervous system (CNS) concentrations and
central OT bioavailability.
Meta-analysis enables statistical pooling of effect sizes
and is a valuable tool for synthesizing results across
studies and increasing power. In the proposed meta-
analysis, we will examine studies in which both central
and peripheral measures of OT have been sampled. This
will enable greater understanding of the dynamics of
neuropeptide release and distribution and help determine
whether peripheral concentration is a reliable marker for
central concentration.
As a primary outcome, an overall summary effect size
for the relationship between central and peripheral
concentrations of OT will be calculated from the effect
sizes of all the individual studies included in the review.
Since central and peripheral samples of OT have been
obtained simultaneously in several species, the relevant
population will not be limited to humans. This summary
effect size will also generalize across experimental para-
digms and interventions. Additional primary outcomes
include summary effect sizes for the relationship between
central and peripheral concentrations of OT assessments
within species category and within experimental paradigm
category (see below for details). The impact of other
moderators will be treated as secondary outcomes.
Methods/design
Aims
The present study is a meta-analysis of available studies
where coordinated central and peripheral measures of
OT have been sampled. The aim is to examine the rela-
tionship between central and peripheral OT levels, as
well as to provide a rationale for discrepancies between
the results of independent studies. If a significant overall
correlation is observed, then peripheral oxytocin con-
centrations may represent an index of central oxytocin
levels. This protocol is registered with PROSPERO
(CRD42015027864) and has been reported here according
to the PRISMA-P [15] guidelines [see Additional file 1].
The procedures described in this protocol follow recent
recommendations for the meta-analysis of correlational
data [16].
Search strategy
We will conduct a systematic literature search in three
iterations to collect studies that simultaneously measure
central and peripheral concentrations of OT. The speci-
ficity and sensitivity of different search criteria were
examined in a pilot search. In the first iteration, searches
will be performed in PubMed and Embase with the
following combination of terms: (oxytocin) AND (con-
centration* OR level*) AND (plasma OR blood OR
saliva* OR urin*) AND (central OR csf OR "cerebro-
spinal fluid"). Further limits for the search will be set in
order to focus the search on full text articles that were
published between January 1, 1971, and the date in
which the search will be performed. In a second iter-
ation, review articles will be consulted for relevant
citations. Since any combination of terms is unlikely to
exhibit perfect sensitivity to relevant articles, and review
articles are unlikely to review a complete set of relevant
articles, a third iteration will be performed in which
reference lists within studies and citing articles of
selected studies in the first and second iterations will
be examined for remaining studies that include the
critical measures.
Inclusion and exclusion criteria
In this meta-analysis, we will include studies that meet
the following criteria: (a) OT sampled in fluids with
access to central (e.g., local extracellular fluid, cerebro-
spinal fluid) and peripheral (e.g., blood plasma, urine,
saliva) regions of the body; (b) correlations between
central and peripheral concentrations obtainable either
through the article, the authors directly, statistical trans-
formation of available data (e.g., Spearman to Pearson
correlation), or “data scraping” from available scatterplots;
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(c) article published in a peer-reviewed journal between
1971 (discovery of ELISA) and June 2015; and (d) written
in English.
Moderators
Studies that provide simultaneous measures of central
and peripheral OT concentrations are not only heteroge-
neous by the correlations they report, they also differ
from each other on several potentially critical methodo-
logical aspects. These include species examined, partici-
pant characteristics, experimental paradigm, sampling
type, biochemical analysis of OT concentration, as well
as whether or not extraction of neuropeptide from
sampled substance was performed. The following poten-
tial moderator variables will be examined a priori in this
meta-analysis in order to account for heterogeneity in
the literature.
1. Participants and species. Participants include clinical
and non-clinical human populations. Animal studies
will also be included to collect a broader dataset of
studies assessing peripheral and central OT concen-
trations, with species encompassing non-human
primates and other mammals. It is possible that
studies in non-human animals may yield results
differing from those in human studies given differ-
ences in physiology to humans. For example, the
olfactory epithelium covers as much as 50 % of the
rodent nasal cavity [17] whereas the proportion in
humans is only 3–15 % [18, 19]. As intranasal
administration of OT appears to depend on uptake
through the olfactory epithelium for direct entry
into the brain [20], such differences in physiology
moderate effect sizes. Furthermore, within human
studies, we will examine whether effect sizes are
moderated by (a) gender of participants, (b) presence
or absence of physical illness, and (c) presence or
absence of psychiatric diseases.
2. Experimental paradigms. These range from the
examination of baseline levels of central and
peripheral OT [13, 21], and levels following some
environmental stimulus such as light [22], and
stressors [7, 23], to examinations of concentrations
after manipulation of OT levels by osmotic
stimulation [9], drug administration [24–26],
or the administration of intranasal [14, 27] or
intraperitoneal [27] OT.
Since the pharmacokinetics of OT seem to exhibit
quite complex, time-dependent patterns [9], there is
a possibility that differences in experimental designs
account for differences in correlations between
studies. For this moderator, (a) baseline samples, (b)
samples after exogenous intranasal OT administra-
tion, (c) samples after intravenous or intraperitoneal
OT administration, (d) samples after intracerebral
OT administration, and (e) samples after other
experimental manipulations (e.g., osmotic stimula-
tion) will be treated as levels within the experimental
paradigms moderator variable. In studies that report
both baseline correlation and correlations after
manipulation, the baseline sample will be assigned to
the baseline level in the moderator analysis,
while experimental samples will be assigned to
experimental levels.
3. Sampling types. These include CSF concentrations
and concentrations in central extracellular fluids,
and measures of concentrations in peripheral blood,
urine, and saliva. A number of discrepancies have
been seen in reports of OT concentration measures.
For example, urine samples have been reported to
give OT concentration estimates at a million times
above usual values for plasma samples [28].
Furthermore, in a study on OT levels in parents
interacting with their infants, Feldman et al. [29]
found no correlation between urine concentrations
of OT and concentrations in blood plasma or saliva.
In studies that administer OT intranasally, large
amounts of the neuropeptide may be drawn through
the floor of the nasal vault, missing nose-to-brain
targets in the upper posterior regions, down to the
oral mucosa and gastrointestinal tract. In these
cases, it is difficult to distinguish between exogenous
OT that has dripped down into the oral cavity and
salivary OT that represent systematically circulating
levels. Indeed, saliva OT has been examined for
its validity as a biomarker, with negative results
reported [30].
4. Method for biochemical analysis of OT concentration.
Two main methods for biochemical detection of
sampled substance are reported in the literature:
enzyme immunoassay (EIA) and radioimmunoassay
(RIA). In a validation procedure directed at these
methods, Christensen et al. [31] found that RIA was
more sensitive to low concentrations of OT and that
concentration estimates provided by RIA
corresponded more closely to estimates by highly
specific two-dimensional liquid chromatography-
tandem mass spectrometry assay [32, 33]. Thus,
studies that employ EIA might exhibit increased
amounts of noise and accordingly weakened correla-
tions between central and peripheral oxytocin. An-
other related concern regarding biochemical analysis
of OT concentration is whether or not neuropep-
tides are extracted from the sampled substance prior
to EIA or RIA.
Extraction of neuropeptides from the sampled
substance is not universal among studies [31, 34].
Measures taken from raw substance are more
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susceptible to cross-sensitivity, resulting in values
that reflect variability of unrelated molecules in
addition to the true level of oxytocin [34, 35]. Szeto
et al. [36] found estimates of OT concentrations
using EIA to be two orders of magnitude higher in
non-extracted plasma as compared to extracted,
additionally finding no significant association
between OT level estimates from extracted and
non-extracted plasma. Thus, there is a possibility
that studies where substances are extracted prior to
immunoassay provide more accurate correlations
between central and peripheral oxytocin if collected
simultaneously. In addition, Szeto et al. [36] found
that while EIA estimates increased a 100-fold in
extracted plasma as compared to non-extracted,
extraction did not increase sensitivity of biochemical
analysis using RIA. There seems, in other words, to
be an interaction effect of analysis method and
extraction on OT concentration estimates.
Accordingly, there might be an interaction effect
of analysis method and extraction on estimates of
correlations between central and peripheral OT
concentrations. Therefore, in this meta-analysis,
the moderator biochemical analysis method
contains two variables with two levels each (RIA
vs EIA, and extraction prior to immunoassay or
not), and we will examine the main effects of
both variables as well as interaction effects.
5. Age. CSF concentrations of OT seem to be related to
age in macaque monkeys, decreasing with age in
infants while increasing with age in mothers [37].
Changes in the oxytocin system with age [38, 39]
may also involve the extent of coordinated release or
even the degree to which OT may penetrate the
blood brain barrier.
6. Risk of bias. A risk of bias tool has been developed
to quantify potential biases in effect sizes related to
study quality (see below).
7. Year of publication. Early, more preliminary studies,
may potentially exhibit different effect sizes, so year
of publication is included as an additional moderator
to assess bias.
8. Level of sample coordination. In some studies,
central and peripheral samples are collected
simultaneously, whereas in others, there is a brief
interval between central and peripheral samples [21].
In this meta-analysis, levels of sample coordination
will be coded as simultaneous or non-simultaneous.
Quality assessment (risk of bias)
A custom tool will be developed to assess risk of bias via
a systematic procedure for determining the quality of
eligible studies [see Additional file 2]. The risk of bias
tool is adapted from a previously used tool [40]. Using
this tool, studies will be given a score of potential bias
by two raters. This tool, in combination with publication
bias (described below), will be used to assess the quality
of overall evidence. The evidence will be categorized as
high (no evidence of publication bias and mean quality
scores are ≥80 %), moderate (little-to-no publication bias
and quality scores are ≥50 and <80 %), low (evidence of
publication bias and quality score ≥50 %), or very low
(evidence of publication bias and quality score <50 %).
Data extraction and management
A summary effect size for all studies will be computed
with effect sizes (correlations transformed to Fisher’s z)
and sample sizes from individual studies as input. Effect
sizes will be extracted using one out of four possible
procedures, depending on whether and in what form
effect sizes are reported in a study. First, if effect sizes
are reported, these will be transformed to Fisher’s z.
Secondly, if effect sizes are not reported but individual
results are reported numerically, r will be calculated and
transformed to z. Thirdly, in studies published after
2000 (as 15 years is a common time frame for the reten-
tion of clinical data) that do not report effect sizes or
individual results in numerical form, authors will be
contacted and asked to provide the relevant information.
Fourth, in studies either published before 2000 or where
authors do not respond to our request, and where all
individual results are reported in scatterplot graphs, a
plot digitizer (http://arohatgi.info/WebPlotDigitizer) will
be used for conversion into numerical values, from
which r will be calculated and transformed to z. Studies
that do not fall into one of these four categories do not
provide the data that is necessary for our analysis and
will not be included in the meta-analysis.
Two independent reviewers will extract data from all
eligible studies using the data extraction form [see
Additional file 3]. This form includes (a) general infor-
mation on studies including authors, title, number of
effect sizes, sample size, and effect sizes; (b) information
about the participants including species, gender, age, and
physical and mental health status; (c) information about
the level the study is on other moderator variables,
including study type, biochemical analysis, and neuro-
peptide extraction; as well as (d) information concerning
study quality including publication year and the risk of
bias measures as defined by the custom risk of bias tool.
Any disagreements will be adjudicated by author DSQ.
The data will be entered into an excel version of the
data extraction form, with one excel sheet for each
reviewer. For each study, the extracted data will be
entered in a separate tab of the data extraction excel
sheet. After the data extraction phase of this meta-study,
the data will be saved as .csv files and treated as data
frames in R for analysis. Data from studies initially
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selected based on title and abstract and articles included
in the review will be documented. Reasons for the exclu-
sion of retrieved articles will also be recorded for even-
tual documentation in a study search and data
extraction flow diagram.
Statistical analysis
Analysis will be performed with R statistical software
version 3.1.1. [41], using the metafor [42] and robu-
meta [43] packages. All effect sizes will be converted
to Fisher’s z prior to analysis, and back to Pearson’s
r after analysis. Operations needed for the analysis
include the following:
Summary effect size
Since the designs of individual studies vary substantially
(e.g., differing species, biochemical methods), real effect
sizes of individual studies should vary accordingly. Thus,
a random effects model is appropriate in the computa-
tion of summary effect size [44]. Summary effect size as
well as confidence interval and statistical significance of
effect size will be computed in R. In the case of studies
reporting more than one correlation, Robust variance
estimation will be used with adjusted estimators for
small samples (n < 40), if necessary.
Sample heterogeneity
The Q-statistic is the sum of the products of weights
and squared differences between study effect sizes
and summary effect sizes. As such, it is an expression
of the heterogeneity of effect sizes in the sample. A
significant Q-statistic is indicative of significantly dif-
ferent effect sizes between the studies included in the
meta-analysis. In this meta-analysis, we follow the
convention of an alpha level of .05 for the Q-statistic.
I2 reflects the proportion of total variance that is
attributable to real between studies variance. The I2
statistic is useful for determining whether the amount
of real between studies effect size variance is rela-
tively higher than chance variability. The Q-statistic,
the significance of the Q-statistic, and I2 will be
computed and reported.
Categorical moderator analysis
A random effects model with separate estimates of
between studies variance will be applied for all categor-
ical moderator variables (species, paradigm, sampling
type, biochemical method, and extraction). Summary
mean effects are calculated for each subgroup, as de-
scribed in the previous section for summary effect sizes.
T2 is calculated separately for each subgroup. Means are
compared using a two-tailed z-test in order to determine
the probability for the difference of observed means given
equality of true means, assuming normal distribution.
A p value below .05 will be seen as indicative of
moderating properties of the variable in question.
Continuous moderator analysis
For the continuous moderator variables (age, risk of
bias, and year of publication), meta-regression will be
performed to estimate an unstandardized regression
coefficient along with the coefficient’s significance level.
Publication bias
Publication bias will be assessed using the regression
test for funnel plot asymmetry outlined in Egger et al.
[45]. If there is evidence of publication bias, we will
use the Trim and Fill method, which provides a
reasonable approximation of “missing” effect sizes
[46]. With this method, the asymmetric right side of
the funnel (which is the side expected to be effected
by publication bias in the present meta-analysis) is
“trimmed”. The remaining symmetric effect sizes are
then used to re-estimate the center of the funnel,
after which the trimmed effect sizes and their missing
counterpart effect sizes on the left side of the funnel
are “filled”. An estimate of the summary effect size
and variance will then be calculated on the filled
funnel plot as a form of sensitivity analysis to exam-
ine the potential impact of missing studies.
Discussion
There is increasing research on the use of peripheral OT
concentrations to determine relationships to a range of
psychological and neurobiological phenomena. More-
over, levels of peripheral OT are also used to determine
the bioavailability of OT after intranasal administration.
These measures are often used as a proxy for central
levels of OT but it is unknown if these two measures are
in fact related, with mixed results reported in the
literature across species and experimental designs.
Recent debate has also highlighted the need for a more
thorough characterization of OT mechanisms [47, 48]
which includes measures of central and peripheral
OT bioavailability.
This will be the first systematic review and meta-
analysis, to the best of our knowledge, to investigate this
association. An up-to-date synthesis of the available data
will help determine if future research can use peripheral
levels of OT as a measure of central activity or if the
collection of CSF concentration is necessary to make
these conclusions. Alternatively, the proposed meta-
analysis may indicate that central and peripheral OT
concentrations are only related under certain conditions,
such as after exogenous OT administration. Predeter-
mined measures of publication bias and study quality
will be used to describe the confidence in the resulting
body of evidence.
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